Evidence map›Paper›PMID 35455369›Full record

ArticleVaccines2022

Adjuvant Curdlan Contributes to Immunization against

Patrícia Kellen Martins Oliveira-Brito, Gabriela Yamazaki de Campos, Júlia Garcia Guimarães, Letícia Serafim da Costa, Edanielle Silva de Moura, Javier Emílio Lazo-Chica, Maria Cristina Roque-Barreira, Thiago Aparecido da Silva

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Immune evasion byFrontiers in immunology · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Patrícia Kellen Martins Oliveira-BritoDepartment of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.ORCID 0000-0002-1406-4385
Gabriela Yamazaki de CamposDepartment of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.
Júlia Garcia GuimarãesDepartment of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.
Letícia Serafim da CostaDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 14049-900, SP, Brazil.ORCID 0000-0002-3973-7953
Edanielle Silva de MouraDepartment of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.
Javier Emílio Lazo-ChicaInstitute of Natural and Biological Sciences, Federal University of Triângulo Mineiro, Uberaba 38025-189, MG, Brazil.ORCID 0000-0003-1950-1895
Maria Cristina Roque-BarreiraDepartment of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.ORCID 0000-0001-7425-0908
Thiago Aparecido da SilvaDepartment of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.ORCID 0000-0001-5017-6539
Universidade de São Paulo · BRUniversidade Federal do Triângulo Mineiro · BR

Funding

São Paulo Research Foundation 2016/04877-2São Paulo Research Foundation 2018/18538-0São Paulo Research Foundation 2018/19949-4São Paulo Research Foundation 2019/09260-1São Paulo Research Foundation 2019/09261-8São Paulo Research Foundation 2019/13979-1
6 · The paper itself

Abstract

The low efficacy and side effects associated with antifungal agents have highlighted the importance of developing immunotherapeutic approaches to treat

Indexed as

Cryptococcus gattiicurdlanDectin-1immunotherapyβ-glucan peptide

Identifiers

PMID35455369
PMCPMC9030172
OpenAlexW4224220196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.